Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

(Progress Update on Disclosed Matter) Notice of Completion of the Acquisition and Cancellation of the Ninth and Eleventh Series of Stock Acquisition Rights with Exercise Price Adjustment Clauses Issued through a Third-Party Allotment

The Company acquired all of the remaining 9th and 11th Series stock acquisition rights with provisions for adjustment of the exercise price on the acquisition date and subsequently cancelled all of them. As a result, the remaining number of both series of stock acquisition rights became zero.

Worth reading
18Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
8559
Units (number of stock acquisition rights acquired and cancelled)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Acquisition and cancellation of the 9th and 11th Series stock acquisition rights with provisions for adjustment of the exercise price through third-party allotment

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Total issued: 5,000 units for the 9th Series and 30,000 units for the 11th Series. Remaining unexercised: 0 units for the 9th Series and 8,549 units for the 11th Series (before acquisition and cancellation). Remaining after cancellation: 0 units for both the 9th and 11th Series.
Impact on Business Performance
The acquisition and cancellation of these stock acquisition rights will have a minor impact on results for the fiscal year ending March 2027.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalAcquisition and cancellation of the 9th and 11th Series stock acquisition rights with provisions for adjustment of the exercise price through third-party allotment
Number of Stock Acquisition RightsTotal issued: 5,000 units for the 9th Series and 30,000 units for the 11th Series. Remaining unexercised: 0 units for the 9th Series and 8,549 units for the 11th Series (before acquisition and cancellation). Remaining after cancellation: 0 units for both the 9th and 11th Series.
Impact on Business PerformanceThe acquisition and cancellation of these stock acquisition rights will have a minor impact on results for the fiscal year ending March 2027.
Items this document does not state (25)
Number of shares to be issued or disposed ofIssue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offering

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The Company is reporting the implementation and completion of the acquisition and cancellation. The impact on operating results is described as minor. No specific reason for the acquisition and cancellation itself is stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Progress Update on Disclosed Matter) Notice of Completion of the Acquisition and Cancellation of the Ninth and Eleventh Series of Stock Acquisition Rights with Exercise Price Adjustment Clauses Issued through a Third-Party Allotment | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori